About AOM Infusion

AOM Infusion, established in 1994, is a leading specialty infusion provider that focuses on chronic therapy management. The company specializes in providing Intravenous Immunoglobulin (IVIG), biologics, and various other therapies designed to address over 80 distinct chronic conditions. AOM’s services are delivered by skilled infusion nurses, ensuring that patients receive long-term treatment that is both professional and empathetic.

In addition to infusion therapies, AOM Infusion offers an array of support services, including skilled infusion nursing administration, pharmacy services, referral management, insurance verification, and comprehensive patient education and training. The company prioritizes enhancing patient experiences and outcomes through a commitment to clinical excellence and tailored infusion care.

Industry Overview in the United States

The specialty infusion industry in the United States has witnessed significant growth over the past decade, driven by an increasing prevalence of chronic health conditions and advancements in infusion technology. The sector is characterized by a shift towards patient-centric care models, wherein services are increasingly delivered in more comfortable and convenient settings, such as patients' homes or outpatient facilities. This shift is aimed at improving both patient outcomes and satisfaction.

Moreover, the evolving landscape of the pharmaceutical industry, with a robust pipeline of infusible drugs, suggests further expansion in the specialty infusion market. Healthcare providers are increasingly adopting innovative solutions that cater to individual patient needs, thereby enhancing both accessibility and efficacy in treatment.

With the rising demand for specialized infusion therapies, the market is becoming increasingly competitive, prompting firms to differentiate their service offerings. Companies that integrate advanced technologies into their service models, while maintaining a strong focus on quality patient care, are well-positioned to thrive in this dynamic environment.

As regulatory frameworks continue to evolve, the emphasis on quality and compliance remains paramount. This ensures that organizations maintain high standards while navigating the complexities of healthcare regulations, ultimately benefiting patients and enhancing overall care delivery.

Rationale Behind the Deal

The recapitalization of AOM Infusion by Revelstoke Capital Partners aligns with the private equity firm's strategy to invest in high-priority sectors within healthcare. The specialty infusion market presents a compelling opportunity for growth due to the ongoing shift in care settings and the expanding array of available infusible therapies. Revelstoke’s investment is intended to bolster AOM’s service offerings and facilitate further expansion into new therapeutic areas.

Revelstoke’s confidence in AOM stems from the company's strong management and its impressive track record of organic growth. This partnership aims to leverage Revelstoke’s financial resources and strategic guidance to enhance AOM’s operational capabilities and market presence.

About Revelstoke Capital Partners

Revelstoke Capital Partners is a private equity firm based in Denver, Colorado, that specializes in building industry-leading companies within the healthcare services, technology, and health and wellness sectors. Founded by experienced investors, Revelstoke employs a disciplined approach to both organic growth and strategic acquisitions. With approximately $4.8 billion in assets under management, the firm has successfully completed 195 acquisitions since its inception in 2013, which includes 30 platform companies and 165 add-on acquisitions.

By partnering with entrepreneurs and management teams, Revelstoke focuses on executing growth strategies that create exceptional value. Their commitment to fostering innovation and quality in healthcare makes them a notable player in the private equity landscape.

View of Dealert

The investment by Revelstoke in AOM Infusion could prove to be a strategic move, given the rising demand for specialty infusion services. The growing emphasis on chronic condition management and the corresponding increase in the patient population in need of such therapies position AOM well for future success. Furthermore, Revelstoke’s experience in scaling healthcare companies can help AOM enhance its service model and expand its geographic reach.

AOM’s established reputation and patient-centric focus are significant assets that could improve operational efficiency and patient satisfaction as they implement new strategies gleaned from Revelstoke’s expertise. The partnership may also facilitate innovations in service delivery that address market challenges and align with evolving patient needs.

However, while the growth potential is significant, success will depend on how effectively AOM can navigate the competitive landscape and regulatory environment. Ensuring compliance while expanding service offerings will be key to maintaining their leadership position in the specialty infusion space.

Overall, this deal appears to be a calculated investment for both parties. With Revelstoke’s commitment to support AOM's evolution and AOM’s foundational strengths, this partnership may yield substantial returns, reinforcing Revelstoke’s position within the specialty infusion market.

View Original Article